BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections.
AXL: a promising target to treat life-threatening diseases
The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab.
Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Partnerships based on BerGenBio’s pioneering R&D are being employed strategically with:
- MSD (Merck), a global pharmaceutical company, which is supplying KEYTRUDA® for several clinical trials
- ADC Therapeutics SA, a Swiss biotech, with whom BerGenBio has entered a licensing agreement to develop an AXL-ADC
- As well as a network of leading clinical sites and key opinion leaders with whom BerGenBio works to ideally position its investigational product candidates.
BerGenBio retains all rights for the future development and commercialization of its products including companion diagnostics and employs strategic partnerships as needed.